Breadcrumb Navigation

Portrait Friedrich Thienemann

Friedrich Thienemann
Dr. med.

Oberarzt Klinik und Poliklinik für Innere Medizin

Spezialgebiete

  • Allgemeine Innere Medizin (FMH, ÄK Berlin)
  • Infektiologie (DGI, ÄK Berlin)
  • Tropenmedizin (DTMPH, Charité Berlin)

Abteilungen

Kontakt

Tel. +41 44 255 40 89
VCard

Weitere Kompetenzen

  • Lymphadenopathie
  • Unklarer Entzündungszustand
  • Seltene Infektionskrankheiten
  • Interaktion chronischer Erkrankungen mit Infektionskrankheiten
  • Aktive und latente Tuberkulose
  • HIV/AIDS
  • COVID-19
  • Migrants & Minorities Health
  • Internationales Gesundheitsmanagement (MSc International Health)

Werdegang

Seit 2017 Oberarzt, Klinik und Poliklinik für Innere Medizin
Universitätsspital Zürich
Seit 2017 Honorarprofessor, Department of Medicine
University of Cape Town
2012-2017 Senior Medical Officer, Institute of Infectious Diseases and Molecular Medicine, Department of Medicine
University of Cape Town
2012 Senior Medical Officer, Infectious Diseases Referral Clinic, Department of Medicine
GF Jooste Hospital, Cape Town
2009 – 2012 Supernumerary Registrar, Division of Infectious Diseases & HIV Medicine, Department of Medicine
Groote Schuur Hospital, University of Cape Town
2006 – 2009 Medizinische Klinik I für Gastroenterologie, Infektiologie und Rheumatologie, Campus Benjamin Franklin
Charité Universitätsmedizin Berlin
2005-2006 Medical Coordinator und HIV Expert
Médecins du Monde, Irian Jaya, West-Papua, Indonesien
2005 Expert Consultant Pharmakovigilanz, Global Medical Safety & Surveillance
Bayer Healthcare, Berlin

Wichtigste Mitgliedschaften

  • International Union Against Tuberculosis and Lung Disease (Union)
  • Deutsche Tropenmedizinische Gesellschaft (DTG)
  • Deutsche Gesellschaft für Infektiologie (DGI)
  • South African Heart Association (SA Heart)

Forschungsschwerpunkte

  • Direktor der Forschungsgruppe General Medicine & Global Health, Universitätspital Zürich & University of Cape Town.
  • Chief Principal Investigator StatinTB Trial: Preventing tuberculosis relapse and chronic lung disease: a proof-of-concept, double-blind, randomised, placebo-controlled trial to evaluate the safety and efficacy of atorvastatin to reduce inflammation after tuberculosis treatment completion in HIV-infected and HIV-uninfected adults measured by FDG-PET/CT. www.statintb.com
  • Co-Principal Investigator PredictTB: Using Biomarkers to Predict TB Treatment Duration. www.predict-tb.com
  • Lead Investigator: Biomarkers to stratify risk of progression from latent TB infection to disease. Tuberculosis Research Units (TBRU) National Institutes of Health (NIH). National Institute of Allergy and Infectious Diseases.
  • Lead Investigator: FDG-PET/CT findings in household contacts of Drug Resistant Tuberculosis. University of Cape Town.
  • Co-Principal Investigator TUBERCULOSIS-018: A phase IIb, double-blind, randomised, placebo-controlled
    study to evaluate the efficacy, safety and immunogenicity of GSK Biologicals’ candidate tuberculosis (TB) vaccine GSK 692342 against TB disease, in adults aged 18-50 years, living in a TB endemic region. University of Cape Town.
  • Co-Principal Investigator PAPUCO: The Pan African Pulmonary Hypertension Cohort (PAPUCO)
    Registry.
  • Co-Investigator WHF COVID-19 and Cardiovascular Disease Survey.

Publikationen

Zur Publikationsliste

Weiteres

  • World Heart Federation Neglected Cardiac Diseases Expert Chagas Disease
  • World Heart Federation Neglected Cardiac Diseases Expert Rheumatic Heart Disease
  • Board Member, Hatter Institute for Cardiovascular Research in Africa, University of Cape Town